Диссертация (1139687), страница 33

Просмтор этого файла доступен только зарегистрированным пользователям. Но у нас супер быстрая регистрация: достаточно только электронной почты!

Текст из файла (страница 33)

Kozlov [et al.] // Arch Biochem Biophys. – 1999. – Vol. 363. – N 1. – P. 148–154.146. Direct electrochemistry of enzymes from the cytochrome P450 2C family /A. Shukla [et al.] // Electrochemistry Communications. – 2005. – Vol. 7. – N 4. –P. 437–442.147. Direct electron transferbetween cytochromeP450sccandgoldnanoparticles on screen-printed rhodium-graphite electrodes / V. V. Shumyantseva [etal.] // Biosens. Bioelectron. – 2005. – Vol. 21. – N 1. – P. 217–222.208148. Direct electron transfer of cytochrome P450 2B4 at electrodes modifiedwith nonionic detergent and colloidal clay nanoparticles / V. V. Shumyantseva [et al.] //Anal. Chem.

– 2004. – Vol. 76. – N 20. – P. 6046–6052.149. Dodhia, V. R. Engineering human cytochrome P450 enzymes intocatalytically self-sufficient chimeras using molecular Lego / V. R. Dodhia, A. Fantuzzi,G. Gilardi // J Biol Inorg Chem. – 2006. – Vol. 11. – N 7. – P. 903–916.150. Dose-proportionality of oral thioctic acid – coincidence of assessments viapooled plasma and individual data / K. Breithaupt-Grögler [et al.] // Eur J Pharm Sci. –1999.

– Vol. 8. – N 1. – P. 57–65.151. Dresser, G. K. Pharmacokinetic-pharmacodynamic consequences andclinical relevance of cytochrome P450 3A4 inhibition / G. K. Dresser, J. D. Spence,D. G. Bailey // Clin Pharmacokinet. – 2000. – Vol. 38.

– P. 41–57.152. Drug-druginteractionsandcooperativeeffectsdetectedinelectrochemically driven human cytochrome P450 3A4 / S. Sadeghi [et al.] //Bioelectrochemistry. – 2012. – Vol. 86. – P. 87–91.153. Drug Oxidation by Cytochrome P450BM3: Metabolite Synthesis andDiscovering New P450 Reaction Types / X. Ren [et al.] // Chemistry. – 2015. – Vol. 21.– N 42. – P. 15039–15047.154. Eckert, M.

Therapy of neuropathies with a vitamin B combination.Symptomatic treatment of painful diseases of the peripheral nervous system with acombination preparation of thiamine, pyridoxine and cyanocobalamin / M. Eckert,P. Schejbal // Fortschr Med. – 1992. – Vol. 110. – N 29. – P.

544–548.155. Effects of 3-week oral treatment with the antioxidant thioctic acid (alphalipoic acid) in symptomatic diabetic polyneuropathy / K. J. Ruhnau [et al.] // DiabetMed. – 1999. – Vol. 16. – N 12. – P. 1040–1043.156. Effectsofacetyl-L-carnitineoraladministrationonlymphocyteantibacterial activity and TNF-alpha levels in patients with active pulmonarytuberculosis. A randomized double blind versus placebo study / E. Jirillo [et al.] //Immunopharmacol Immunotoxicol.

– 1991. – Vol. 13. – N 1–2. – P. 135–146.209157. Effects of alpha-lipoic acid on microcirculation in patients with peripheraldiabetic neuropathy / E. Haak [et al.] // Exp Clin Endocrinol Diabetes. –2000. –Vol. 108. – N 3. – P. 168–174.158. Effects of B2-deficiency on lipoperoxide and its scavenging system in therat lens / H.

Hirano [et al.] // Int. J.Vitam. and Nutr.Res. – 1983. – Vol. 53. – N 4. –P.377–382.159. Effects of cytochrome p450 3A4 inhibitors – ketoconazole anderythromycin – on bitopertin pharmacokinetics and comparison with physiologicallybased modelling predictions/ C.

Boetsch [et al.] // Clin. Pharmacokinet. – 2016. –Vol. 55. – P. 237–247.160. Effects of protein-protein interactions on electron transfer: docking andelectron transfer calculations for complexes between flavodoxin and c-typecytochromes / C. A. Cunha [et al.] // J Biol Inorg Chem. – 1999. – Vol. 4. – N 3. –P. 360–374.161. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics oflignocaine and its pharmacologically active metabolites in subjects with normal andimpaired liver function / R. Orlando [et al.] // Br J Clin Pharmacol.

– 2003. – Vol. 55. –N 1. – P. 86–93.162. Effects of thiamine deficiency on hepatic cytochromes P450 and drugmetabolizing enzyme activities / J. S. Yoo [et al.] // Biochemical pharmacology. – 1990.– Vol. 39. – N 3. – P. 519–525.163. Effects of treatment with the antioxidant alpha-lipoic acid on cardiacautonomic neuropathy in NIDDM patients. A 4-month randomized controlledmulticenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie /D. Ziegler [et al.] // Diabetes Care.

– 1997. – Vol. 20. – N 3. – P. 369–373.164. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4years in diabetic polyneuropathy: the NATHAN 1 trial / D. Ziegler [et al.] // DiabetesCare. – 2011. – Vol. 34. – N 9. – P. 2054–2060.210165. Electroanalysis of cytochrome P450 3A4 catalytic properties withnanostructured electrodes: the influence of vitamin B group on diclofenac metabolism /A. A.

Makhova [et al.] // BioNanoScience. – 2011. – Vol. 1. – N 1–2. – P. 46–52.166. Electrocatalytic cycle of P450 Cytochrome: protective and stimulatingroles of antioxidants / V. V. Shumyantseva [et al.] // RSC Advances. – 2015. – Vol. 5. –P. 71306–71313.167. Electrochemical Immunosensor Based on Metal Nanoparticles for CardiacMyoglobin Detection in Human Blood Plasma / E. V. Suprun [et al.] // Electroanalysis.– 2011. – Vol. 23. – N 5.

– P. 1051–1057.168. Electrochemical investigations of cytochromes P450 / V. V. Shumyantseva[et al.] // Biochimica et Biophysica Acta (BBA) — Proteins and Proteomics. – 2011. –Vol. 1814. – N 1. – P. 94–101.169. Electrochemical properties of cytochroms P450 using nanostructuredelectrodes: direct electron transfer and electrocatalysis / V. V. Shumyantseva [et al.] //J.

Inorg. Biochem. – 2007. – Vol. 101. – N 5. – P. 859–865.170. Electrochemical reduction of cytochrome P450 using electrodes containingimmobilized substrates / V. V. Shumyantseva [et al.] // Biochemistry (Moscow)Supplement Series B: Biomedical Chemistry. – 2007.

– Vol. 1. – N 2. – P. 77–81.171. ElectrochemicalSensorSystemsforMedicineShumyantseva/V. V. Shumyantseva [et al.] // Nanomedicine in Diagnostics / ed. N. Rozlosnik. –Science Publishers: Enfield, 2012. – Part 4. – P. 68–95.172. Electrochemistry of mammalian cytochrome P450 2B4 indicates tunablethermodynamic parameters in surfactant films / K. D. Hagen [et al.] // Journal ofInorganic Biochemistry.

– 2013. – Vol. 129. – P. 30–34.173. Enantioselective pharmacokinetics and bioavailability of different racemicalpha-lipoic acid formulations in healthy volunteers / R. Hermann [et al.] // Eur J PharmSci. – 1996. – Vol. 4 – P. 167–174.174. Enhancement of glucose disposal in patients with type 2 diabetes by alphalipoic acid / S. Jacob [et al.] // Arzneimittelforschung. – 1995. – Vol. 45. – N 8. –P. 872–874.211175. Ercolani, G. The lidocaine test as an index of hepatic function: its clinicalusefulness in liver surgery / G.

Ercolani, G. L. Grazi, R. Calliva // Surgery. – 2000. –Vol. 127. – N 4. – P. 464–471.176. Evans, W.E. Pharmacogenomics: translating functional genomics intorational therapeutics / W. E. Evans, M. V. Relling // Science. – 1999. – Vol. 286. –N 5439. – P. 487–491.177. Farooq, Y. Kinetics of electron transfer between NADPH-cytochromeP450 reductase and cytochrome P450 3A4 / Y.

Farooq, G. C. Roberts // Biochem J. –2010. – Vol. 432. – N 3. – P. 485–493.178. Faster plasma vitamin E disappearance in smokers is normalized byvitamin C supplementation / R. S. Bruno [et al.] // Free Radic Biol Med. – 2006. –Vol. 40. – N 4. – P. 689–697.179. Feinstein, A.

R. Pre-therapeutic classification of comorbidity in chronicdisease / A. R. Feinstein // J. Chron. Dis. – 1970. – Vol. 23 – N 7. – P. 455–468.180. Functional characterisation of an engineered multidomain human P450 2E1by molecular Lego / M. Fairhead [et al.] // J Biol Inorg Chem. – 2005. – Vol. 10. – N 8.– P. 842–53.181. Galdhar, N. R.

Hepatic drug metabolism and lipid peroxidation in thiaminedeficient rats / N. R. Galdhar, S. S. Pawar // Int J Vitam Nutr Res. – 1976. – Vol. 46. –N 1. – P. 14–23.182. Galteau, M. M. Urinary 6beta-hydroxycortisol: a validated test forevaluating drug induction or drug inhibition mediated through CYP3A in humans and inanimals / M. M. Galteau, F. Shamsa // Eur.

J. Clin. Pharmacol. – 2003. – Vol. 59. –N 10. – P. 713–733.183. Gardiner, S. J. Pharmacogenetics, Drug-Metabolizing Enzymes, andClinical Practice / S. J. Gardiner, E. J. Begg // Pharmacol. Rev. – 2006. – Vol. 58. –P. 521–590.184. Gene expression of p-glycoprotein and cytochrome p450 3A4 in peripheralblood mononuclear cells and correlation with expression in liver / C.

Y. Lee [et al.] //Transplant Proc. – 2010. – Vol. 42. – N. 3 – P. 834–836.212185. Glutathione transferases and the detoxication of products of oxidativemetabolism / B. Mannervik [et al.] // Microsomes and drug Oxidations / ed.A. R. Boobis [et al.]. – London: Taylor and Francis, 1985. – P. 221–228.186. Guengerich, F. P. Cytochrome P-450 3A4: regulation and role in drugmetabolism / F. P. Guengerich // Annu Rev Pharmacol Toxicol. – 1999. – Vol. 39 –P.

1–17.187. Guengerich, F. P. Rate-limiting steps in cytochrome P450 catalysis /F. P. Guengerich // Biol Chem. – 2002. – Vol. 383. – N 10. – P. 1553–1564.188. Guengerich, F. P. Human Cytochrome P450 Enzymes/ F. P. Guengerich //Cytochrome P450. Structure, mechanism, and biochemistry / ed. P. R. Ortiz deMontellano – 4th ed. – Cham: Springer International Publishing Switzerland, 2015. –Part II.

– Vol. 2. – Ch. 9. – P. 523–786.189. Guilbault, G. G. General considerations / G. G. Guilbault // EnzymaticMethods of Analysis, International Series of Monographs in Analytical Chemistry,Vol. 34 / ed. H. Bisswanger. – New York: Pergamon Press Inc., 1970. – Ch. 1. – P. 1–24.190. Hardwick, J. P. Cytochrome P450 omega hydroxylase (CYP4) function infatty acid metabolism and metabolic diseases / J. P.

Характеристики

Список файлов диссертации